Response was assessed by BILAG-based Composite Lupus Assessment (BICLA) response at Week 24. Univariate/multivariate analyses were performed, with 22 previously determined potential predictors. Stepwise multivariate analysis included univariate predictors with p<0.05; persistent disease (vs acute flare; p=0.040), low C3 and/or C4 (vs normal; p=0.005), low C4 (vs normal; p=0.007), low C3 (vs normal; p=0.042), and SLEDAI-2K score ≥10 (vs <10; p=0.044) (figure 1). In the multivariate stepwise analysis, significant predictors of BICLA non-response (odds ratio [OR]; [95% confidence interval]; p<0.05) were persistent disease (vs acute flare; 0.047 [0.004, 0.491]; p=0.011) and low C4 (vs normal; 0.094 [0.010, 0.857]; p=0.036).

To explore the impact of identified predictors, subgroup analyses showed a higher proportion of patients with acute flare without low C3/C4 (n=10) achieved BICLA response at Week 24 vs patients with acute flare and low C3/C4 or persistent disease activity (n=33) (80.0% vs 24.2%; p=0.005 for OR vs acute flare; 0.047 [0.004, 0.491]; p=0.011) and low C4 (vs normal; p=0.042), and SLEDAI-2K score ≥10 (vs <10; p=0.044) (figure 1). In the multivariate stepwise analysis, significant predictors of BICLA non-response (odds ratio [OR]; [95% confidence interval]; p<0.05) were persistent disease (vs acute flare; 0.047 [0.004, 0.491]; p=0.011) and low C4 (vs normal; 0.094 [0.010, 0.857]; p=0.036).

Conclusions Acute flare with normal complement predicted high placebo response in this analysis. Recent medical history should be considered when defining SLE study populations.

REFERENCES

MEDICATIONS GIVEN TO PATIENTS WITH INCOMPLETE SYSTEMIC LUPUS ERYTHEMATOSUS

Tatiana Panafidina, Tatiana Popkova*, Liubov Kondrateva, Yulia Gorburova, Anastasia Shumilova, Alexandr Ula. Systemic lupus erythematosus, V.A.Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background Often, patients present with clinical symptoms and immunologic abnormalities suggestive of systemic lupus erythematosus(SLE), while not meeting classification criteria yet. This is referred to as incomplete SLE(iSLE). Timely treatment, however, is important to limit disease progression, and prevent organ damage and mortality. The aim of the study was to evaluate the therapy administered to patients diagnosed with iSLE.

Methods iSLE(n=60) was defined by rheumatologists as a form of lupus, the clinical manifestations of iSLE can be significant. This may explain why many iSLE patients are treated with immunomodulatory medications.

Results A large proportion of iSLE patients (55%) were prescribed hydroxychloroquine at a dose of 200 mg/day and oral corticosteroids (42%), the maximum dose of prednisolone was 15[6–40]mg/day. Five (8%) patients with iSLE were taking immunosuppressants: sulfasalazine-2(4%), methotrexate-1(2%), azathioprine-1(2%), and cyclophosphamide -1(2%). Six (10%) iSLE patients were taking biologic: rituximab -1(2%), IL-6 inhibitor – 1(2%), intravenous human immunoglobulin – 4 (7%). Other medicines: NSAIDs – 28%, vitamin D – 27%, course of antibiotics – 18%, low dose aspirin – 17%, anticoagulants – 10%, anipsychotics – 5%, etrombopag and antithrombines – 2% each of patients.

Conclusions Although iSLE is sometimes considered a mild form of lupus, the clinical manifestations of iSLE can be significant. This may explain why many iSLE patients are treated with immunomodulatory medications.

SLE OVERLAP WITH PSORIATIC ARTHRITIS SUCCESSFULLY TREATED WITH SECUKINUMAB

Athina Theodoridou*, Δ Internal Medicine Clinic, Hippokrateion Hospit, Academic fellow Rheumatology Dept., Δ Internal Medicine Clinic, Hippokrateion Hospital Thessaloniki, Greece

Description Background: Psoriasis is a chronic disease of the skin that often affects joints and IL17 has a pathogenetic role. It has been reported that interleukin-17 (IL-17) and Th17 cells play important roles in the pathogenesis of SLE; amplifies the immune response by inducing the local production of chemokines and cytokines, recruiting neutrophils and monocytes, augmenting the production of autoantibodies, and aggravating the inflammation. Secukinumab is an anti-IL-17 monoclonal antibody with approval for use in AS and Psoriatic arthritis. There are few reports on interleukin-17-targeted therapy in SLE. Objectives: We report a case SLE overlapped with psoriatic arthritis, successfully treated with Secukinumab.

Methods 32 y.o.man diagnosed with psoriasis on 2016, started having arthralgia on 2018 simultaneously with a new facial rash. Skin biopsy revealed lupus erythematosus tumidus. Gradually he developed fatigue, photosensitivity, low back pain and arthritis of hand, feet hip joints. Laboratory profile: ANA 1/160 homogeneous, antigDNA neg, C3, C4 normal, lupus anticoagulant positive, all the other autoantibodies negative.

X-rays showed MCP MTP hand DIP stenosis, and sacroiliitis. PASI score 3

First he was treated with Plaquenil and Medrol with improvement in lupus rash and failure both in arthritis and psoriasis. We then added methotrexate and subsequently cyclosporine but all combinations failed to control arthritis.

Results After one year of treatment failures we offered him a combination of Plaquenil, sc Methotrexate and Secukinumab 300 mg/4 weeks. After six months with Secukinumab treatment SLE is inactive and psoriatic arthritis has low disease activity. PASI score 1. No adverse events were observed in terms of SLE.

Conclusions Although recent studies have begun to shed light on the role of IL-17 in the pathogenesis of SLE, there is no experience in real world yet. This case report adds on to our experience on results and safety of Secukinumab in Lupus.


Lupus Sci Med first published as 10.1136/lupus-2023-KCR.271 on 6 August 2023. Downloaded from http://lupus.bmj.com/ by guest. Protected by copyright.